Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer and liver cancer. Provectus investigational oncology drug, PV , is an ablative immunotherapy under investigation in solid tumor cancers. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH , its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed Phase trials of PV as a therapy for metastatic melanoma, and of PH as a topical treatment for psoriasis. In addition, Provectus has begun a Phase trial as a therapy for metastatic melanoma. Information about these and the Company s other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company s website at www.provectusbio.com.
Quote | Provectus Biopharmaceuticals Inc (OTCMKTS:PVCT)
Last: | $0.1189 |
---|---|
Change Percent: | -10.74% |
Open: | $0.1196 |
Close: | $0.1189 |
High: | $0.1196 |
Low: | $0.11 |
Volume: | 23,466 |
Last Trade Date Time: | 07/17/2024 03:00:00 am |
News | Provectus Biopharmaceuticals Inc (OTCMKTS:PVCT)
KNOXVILLE, Tenn., June 13, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today that its 2024 annual stockholder meeting (the “2024 Annual Meeting”), including meeting activities and ...
Accelerates wound closure and improves wound healing KNOXVILLE, TN, May 21, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that non-clinical data on Provectus’s proprietary, pharma...
Message Board Posts | Provectus Biopharmaceuticals Inc (OTCMKTS:PVCT)
Subject | By | Source | When |
---|---|---|---|
NEWS -- Provectus Biopharmaceuticals Announces Publication of Activity | Paulness | investorshub | 04/20/2023 12:48:08 PM |
Strong today with decent volume at midday. | Plegee | investorshub | 02/28/2023 5:05:51 PM |
In for a few bushels. Thanks for | dranesthesia1 | investorshub | 02/28/2023 3:12:24 PM |
Yet another bounce off of $0.10 support. | Plegee | investorshub | 02/23/2023 7:55:34 PM |
Look at the tweet under the newsletter tweet https://twitter.com/ProvectusBio/s | Wehalls | investorshub | 01/12/2023 1:14:06 PM |
News, Short Squeeze, Breakout and More Instantly...
Provectus Biopharmaceuticals Inc Company Name:
PVCT Stock Symbol:
OTCMKTS Market:
Provectus Biopharmaceuticals Inc Website:
KNOXVILLE, Tenn., June 13, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today that its 2024 annual stockholder meeting (the “2024 Annual Meeting”), including meeting activities and ...
Accelerates wound closure and improves wound healing KNOXVILLE, TN, May 21, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that non-clinical data on Provectus’s proprietary, pharma...
PDAT clinical outcomes for infectious keratitis from Brazil and Mexico KNOXVILLE, TN, May 14, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that clinical and non-clinical data on rose be...